On November 5, 2025, the Department of New Experimental Therapeutics and Early-Phase 1 Drug Development Service at Kansai Medical University Hospital administered the GSK5460025, developed by GlaxoSmithKline — to the “first patient in the World ” as part of a global, multicenter First-in-Human Phase 1 Clinical Trial (ClinicalTrials.gov ID: NCT07213609).  The administration took place in Kansai Medical University Hospital.

Study Details | NCT07213609 | A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors | ClinicalTrials.gov